News | July 29, 2022
Alniche Lifesciences celebrates 15 anniversary
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.
The company has posted net profit of Rs.39.71 crores for the Financial Year ended March 31, 2022.
The drug will be manufactured at the group’s topical facility at Ahmedabad
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
The key categories include intimate wellness, skincare & hair care
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Zydus unveils its ‘innovation and care’ centric corporate brand identity
Subscribe To Our Newsletter & Stay Updated
